4/A: AN2 Therapeutics Executive Kevin Krause Amends Filing on Stock Vesting
SEC Filing
Kevin Michael Krause, Chief Strategy Officer of AN2 Therapeutics, amends a previous Form 4 filing to clarify the vesting schedule for restricted stock units.
Summary
- Kevin Michael Krause, Chief Strategy Officer of AN2 Therapeutics, filed an amended Form 4 with the SEC on March 29, 2024.
- The amendment pertains to a previous transaction reported on March 18, 2024, regarding the vesting schedule of restricted stock units.
- The amended filing clarifies that 1/4th of the shares vest annually over four years from January 1, 2024, contingent upon continuous service.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects transparency.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.
Stakeholder Impact
- Shareholders are informed about the vesting schedule of executive stock options, promoting transparency.
Key Dates
| Date | Description |
|---|---|
| 2023/12/14 | Date of Power of Attorney execution. |
| 2024/01/01 | Start date for the vesting schedule of restricted stock units. |
| 2024/03/15 | Date of the transaction involving common stock. |
| 2024/03/18 | Date of original Form 4 filing. |
| 2024/03/29 | Date of amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.